Epocrates Cancels IPO

Epocrates Inc., a San Mateo, Calif.-based provider of clinical information and support tools to healthcare professionals, has withdrawn plans for a $75 million IPO. It had planned to trade on the Nasdaq, with Citi serving as lead underwriter.


In a letter to the SEC, Epocrates said that the IPO would have been “discretionary financing.”


The company has raised over $86 million in VC funding, from firms like The Sprout Group (17% stake), Goldman Sachs (16%), InterWest Partners (12.7%), Draper Fisher Jurvetson (10.4%), Three Arch Partners (10.3%) and Bay City Capital (7.3%). www.epocrates.com

Take your pick!

  • Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
  • VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.